Alex Goldberg

NASDAQ Decliners Watch List: Amarin Corporation plc (NASDAQ:AMRN) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 04/15/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Amarin Corporation plc (NASDAQ:AMRN) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Amarin Corporation plc (NASDAQ:AMRN) a biopharmaceutical company that focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases is currently down (-4.45%) on 1,224,063 shares traded after an update in the FDA's Orange Book regarding the company's drug Vascepa. Amarin Corporation plc (NASDAQ:AMRN) is currently down (-55.2%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Amarin Corporation plc (NASDAQ:AMRN)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases is currently down (-2.16%) on 948,972 shares traded after SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exibits. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently down (-13.04%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com